New therapies for human immunodeficiency virus (HIV)infected patients suggest the need to examine whether these therapies are as effective in older patients as in younger patients. Fifty-two patients aged у50 years were compared with 52 patients aged !50 years for changes in CD4 + counts, viral loads, opportunistic disease, hospitalizations, drug side effects, and death. No differences were found, except for higher rates of candidiasis in younger patients. Antiretroviral therapy seems to be equally effective in older and younger patients.
Several studies have examined the effect of aging on the natural history and progression of HIV infection. A study of 1300 hemophiliacs (for whom dates of seroconversion were known) showed that, compared with individuals who were 18-34 years of age, persons who were 35-70 years of age were more likely to have HIV infection progress to AIDS during a given period [1] . Another study of 88 hemophiliacs demonstrated similar results [2] . A long-term follow-up study of 122 patients, who were analyzed according to both age and HIV load, showed that the risk of developing AIDS increased at a rate of 3% per year of age and that the risk was independent of the viral load [3] . The risk of progression of HIV infection in association with age has been shown to be independent of the risk factor for infection [4] . Other studies have shown that greater age was related to more-rapid progression of HIV disease and higher rates of death among older patients [5] [6] [7] [8] . Greater age has also been related to an increased likelihood of opportunistic disease [9] . This difference in progression has been explained by the decline in immune function that accompanies aging [9] [10] .
However, all of these cohort studies were done before the era when effective antiretroviral therapy (ART) and prophylaxis for HIV-related infections began to be used. Prophylaxis has been shown to reduce the probability that an HIV-positive person will develop certain opportunistic diseases, and ART has been shown to arrest and reverse the progression of HIV disease [11] . Therefore, we sought to investigate whether the progression of HIV disease in older persons has been altered since the advent of effective treatment.
Patients and methods. We identified 52 HIV-infected men who were у50 years of age at the time that they began receiving care at the Houston Veteran's Administration Medical Center's (VAMC) HIV clinic during 1986-1998. A cutoff age of 50 years was chosen because it was the midpoint of ages (140, 150, 155, and 160 years) that had been defined as "older" in previous studies [12] [13] [14] [15] . A total of 52 HIV-infected men who were !50 years of age and who were receiving care during the same period as were the HIV-infected patients у50 years of age were randomly selected and were used as a comparison group.
The charts of these 104 patients were reviewed to determine whether there were differences in the care received by and/or the outcomes for younger patients versus older patients in the era of ART. Data collected for purposes of comparison were as follows: first and last CD4 ϩ T lymphocyte counts and viral loads recorded at the VAMC, risk factors for infection, length of time that care for HIV infection was received at the VAMC, presence of HIV-related opportunistic disease, number of hospitalizations, side effects of antiretroviral drugs (which the attending clinician noted in each chart as a side effect associated with the ART regimen), death, and whether recommended ART had been received. "Recommended ART" was defined as a combination of antiretroviral drugs that included a protease inhibitor and 2 nucleoside reverse-transcriptase inhibitors, as recommended by the US Public Health Service in May 1998 [16] . Regimens that included a nonnucleoside reverse-transcriptase inhibitor were excluded because they were not recommended as approved therapies until December 1998. Patients were not considered to have received recommended therapy unless they had received such therapy for у3 months.
The 2 cohorts were compared to determine whether there were differences between the groups with regard to the aforementioned risk factors. The significance of any differences was determined by use of analysis and t-tests. Results that were 2 x found to be !.05 were considered significant.
Results. The 2 patient groups were similar in most respects, with the exception of age (table 1) . There was a statistical difference ( ) between the groups with regard to the length P ! .05 of time that care was received, with younger patients receiving care for a longer period. This difference in the length of care received was ∼13 months, and it can be explained by the fact that 9 of the older patients died, compared with only 2 of the younger patients. This truncated the older patients' average Neck, back, and abdomen pain 1 4
Kidney stones and polyuria 1 3
Headache and dizziness 1 1
Perioral paresthesia and taste problems 0 4
Other 4 5
NOTE. Statistical analysis of these data was not done because the same person could have had 11 side effect. time in care and made the average less than that for younger patients. There were no significant differences between the 2 groups with regard to the rate of development of opportunistic infections or the development of drug-related side effects. The number of hospitalizations was similar between the groups. In the era of ART, it would be expected that CD4 ϩ T lymphocyte counts would increase and that HIV loads would decrease. A comparison of the first and last viral loads and CD4 ϩ T lymphocyte counts that were obtained showed that the changes were as expected. With regard to the HIV load and CD4 ϩ T lymphocyte count, the differences between the 2 patient groups had neither clinical nor statistical significance. The mortality rate was higher among patients who were у50 years of age than among those who were !50 years of age (18% vs. 6%;
), but when the data were examined according to cause P p .06 of death, there were no significant differences in the number of AIDS-related deaths. Non-HIV-related causes of death were identified for 4 of the older patients (cardiac tamponade, cardiac arrhythmia, lung cancer, and gastric cancer) and for 1 of the younger patients (hepatoma) (table 2). There also were no differences between the patient groups with regard to the types of side effects experienced (table 3) . No significant differences in the presence of HIV-related opportunistic diseases were noted, except that younger patients were more likely to have had candidiasis (table 4) .
Discussion. Given that previous studies have suggested that older patients were more likely than younger patients to have poorer outcomes, the lack of difference in the outcome measures for the groups was unexpected. This suggests that prior research might not be valid when ART is used for older patients. It is also significant that the older patients did not develop more or different drug-related side effects than did the younger patients (table 3) . This suggests that there should be no unusual concerns about using ART for older patients.
In the present study, we also examined whether the similar outcomes among younger patients and older patients were the result of differences in the use of ART in the 2 groups. This was difficult to determine. During the study period (1986-1998), a wide variety of treatments were used, and they changed over time. Sixty-four of the patients received their first HIV-related care at the VAMC before the advent of tripledrug combination therapy in 1996. Of these 64 patients, 32 (17 of whom were у50 years of age and 15 of whom were !50 years of age) did not receive approved therapies. Nine of Downloaded from https://academic.oup.com/cid/article-abstract/34/11/1530/369594 by guest on 30 December 2018 these patients died before 1996, so they did not have the opportunity to receive triple-drug therapy.
Other patients entered clinical trials that used therapies that were not approved at the time of the trial but that have since been approved. Of the 44 patients who were not receiving the therapies recommended in 1998, 17 (8 of whom were !50 years of age) were receiving therapies that have since been recommended as appropriate therapy. These 17 patients included 1 patient who was receiving amprenavir, 6 who were receiving abacavir, and 11 who were receiving efavirenz. Six patients (3 from each age group) who were seen before 1996 had initially been given dual therapy. These 6 patients were doing well clinically and, therefore, continued receiving dual therapy either because they chose to do so or because their clinician did not want to change a successful therapy. Nine patients (6 of whom were !50 years of age) initially received recommended tripledrug therapies, but such therapy failed to achieve the desired clinical results. Therapy for these patients was then switched to salvage regimens, which used a variety of drug combinations.
Finally, 3 patients (1 of whom was !50 years of age) refused to receive ART, even though it had been recommended to them. Therefore, the study assessed the criterion of whether there was a difference in therapy used for the 2 groups by examining the proportion of patients who were receiving therapies that were recommended by the guidelines in force in 1998 [12] . Table 1 shows that approximately the same proportion of patients in both groups received recommended therapy (53% of the older patients vs. 60% of the younger patients). There were no significant differences between the 2 groups with regard to participation in trials or receipt of 2-drug regimens or salvage therapies.
It was not possible to determine whether patients had received appropriate prophylactic therapy. Recommendations regarding which agents to use and when to initiate and discontinue their use changed multiple times during the study. The lack of consistency of the recommendations precluded an examination of whether the patients received appropriate prophylaxis.
Conclusions. These results may indicate that successful treatment with ART is sufficiently effective and that it overcomes the natural disadvantages associated with advancing age. These findings can be supported by the fact that the older patients in this study had increases in CD4 ϩ T lymphocyte counts that were comparable to those observed in the younger patients, even though a previous study had suggested that older HIV-infected patients were unable to replenish these cells as rapidly as were younger individuals [10] . These results provide evidence that there should be no difference in the management of older and younger HIV-infected patients. The standard approach to therapy (i.e., ART) seems to produce the same out-comes without causing any additional side effects. Clinicians should also expect to see the immune function and HIV loads of older patients show improvements similar to those seen in younger patients. Therefore, because treatment outcomes seem to be the same for both groups, clinicians should judge the effectiveness of therapy for older HIV-infected patients in the same manner that they judge the effectiveness of therapy for younger HIV-infected patients.
